Deyali Chatterjee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3986335/publications.pdf

Version: 2024-02-01

61 papers	2,199 citations	304602 22 h-index	243529 44 g-index
61 all docs	61 docs citations	61 times ranked	3966 citing authors

#	Article	IF	Citations
1	Enterochromaffin-like Cell Hyperplasiaâ€“Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use. Archives of Pathology and Laboratory Medicine, 2022, 146, 366-371.	1.2	10
2	Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. Modern Pathology, 2022, 35, 554-563.	2.9	9
3	Clinical classification of symptomatic heterotopic pancreas of the stomach and duodenum: A case series and systematic literature review. World Journal of Gastroenterology, 2022, 28, 1455-1478.	1.4	11
4	Hepatic Secondary Syphilis Can Cause a Variety of Histologic Patterns and May Be Negative for Treponeme Immunohistochemistry. American Journal of Surgical Pathology, 2022, 46, 567-575.	2.1	6
5	Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome. Abdominal Radiology, 2022, 47, 3971-3985.	1.0	2
6	Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut, 2021, 70, 148-156.	6.1	139
7	Intraepithelial tumour infiltrating lymphocytes are associated with absence of tumour budding and immature/myxoid desmoplastic reaction, and with better recurrenceâ€free survival in stages Iâ€“III colorectal cancer. Histopathology, 2021, 78, 252-264.	1.6	23
8	Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 319-326.	1.4	16
9	Tumor Evolution in a Patient with Recurrent Endometrial Cancer and Synchronous Neuroendocrine Cancer and Response to Checkpoint Inhibitor Treatment. Oncologist, 2021, 26, 90-96.	1.9	3
10	Adenoma-like adenocarcinoma: clinicopathologic characterization of a newly recognized subtype of colorectal carcinoma. Human Pathology, 2021, 107, 9-19.	1.1	4
11	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. Journal of Clinical Oncology, 2021, 39, 911-919.	0.8	34
12	Assessing Rectal Cancer Treatment Response Using Coregistered Endorectal Photoacoustic and US Imaging Paired with Deep Learningï»¿. Radiology, 2021, 299, 349-358.	3.6	17
13	Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. Cancers, 2021, 13, 3817.	1.7	15
14	Single institutional experience on primary neuroendocrine neoplasms of the kidney: a rare distinct entity. Human Pathology, 2021, 114, 36-43.	1.1	7
15	Hepatocellular adenomas: Understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. Journal of Magnetic Resonance Imaging, 2020, 51, 1630-1640.	1.9	20
16	Encyclopedia of endometriosis: a pictorial rad-path review. Abdominal Radiology, 2020, 45, 1587-1607.	1.0	20
17	Clinicopathologic determinants of pathologic treatment response in neoadjuvant treated rectal adenocarcinoma. Annals of Diagnostic Pathology, 2020, 45, 151452.	0.6	6
18	Poorly formed hepatic granulomas: a rare manifestation of acute T cellâ€mediated rejection. Histopathology, 2020, 77, 847-848.	1.6	2

#	Article	IF	Citations
19	Well-differentiated rectal neuroendocrine tumors: analysis of histology, including insulinoma-associated protein 1 expression, and biologic behavior, involving a large cohort of 94 cases. Human Pathology, 2020, 104, 66-72.	1.1	7
20	Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications. Archives of Pathology and Laboratory Medicine, 2020, 144, 838-845.	1.2	20
21	Real-time colorectal cancer diagnosis using PR-OCT with deep learning. Theranostics, 2020, 10, 2587-2596.	4.6	34
22	Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms. Pancreas, 2020, 49, 255-260.	0.5	11
23	Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. Modern Pathology, 2020, 33, 1410-1419.	2.9	13
24	Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience. Annals of Surgical Oncology, 2020, 27, 3542-3550.	0.7	6
25	ASO Author Reflections: Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience. Annals of Surgical Oncology, 2020, 27, 3551-3552.	0.7	1
26	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
27	Results of Treatment of a Biliary Cystadenoma by Unroofing and Fulguration in a Female. American Surgeon, 2020, , 000313482095631.	0.4	0
28	Insulinomaâ€associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. Histopathology, 2019, 75, 568-577.	1.6	37
29	Transgenerational impact of maternal obesogenic diet on offspring bile acid homeostasis and nonalcoholic fatty liver disease. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E674-E686.	1.8	23
30	Follicular cholecystitis: clinicopathologic associations. Human Pathology, 2019, 88, 1-6.	1.1	8
31	The Angular Spectrum of the Scattering Coefficient Map Reveals Subsurface Colorectal Cancer. Scientific Reports, 2019, 9, 2998.	1.6	13
32	Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib. ACG Case Reports Journal, 2019, 6, e00011.	0.2	8
33	Dysplasia in Gallbladder: What Should We Do?. Journal of Gastrointestinal Surgery, 2019, 23, 686-689.	0.9	6
34	Significance of T1a and T1b Carcinoma Arising in Mucinous Cystic Neoplasm of Pancreas. American Journal of Surgical Pathology, 2018, 42, 578-586.	2.1	16
35	Residual Tumor Index. American Journal of Surgical Pathology, 2018, 42, 1480-1487.	2.1	18
36	Mucinous Small Bowel Adenocarcinoma Mimicking Change to Internal Penetrating Phenotype in Well-controlled Crohn's Disease. American Journal of Gastroenterology, 2018, 113, 1732-1733.	0.2	2

#	Article	IF	Citations
37	Label-free quantitative optical assessment of human colon tissue using spatial frequency domain imaging. Techniques in Coloproctology, 2018, 22, 617-621.	0.8	7
38	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2018, 24, 5883-5894.	3.2	76
39	Feasibility of co-registered ultrasound and acoustic-resolution photoacoustic imaging of human colorectal cancer. Biomedical Optics Express, 2018, 9, 5159.	1.5	53
40	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer Research, 2017, 77, 2647-2660.	0.4	113
41	Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. American Journal of Surgical Pathology, 2017, 41, 1097-1104.	2.1	62
42	The prognostic significance of infiltrating lymphocytes in resectable pancreatic ductal adenocarcinoma in untreated versus neoadjuvant treated patients. Annals of Oncology, 2017, 28, v250-v251.	0.6	0
43	Transforming Growth Factor-Î² Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clinical Cancer Research, 2016, 22, 4934-4946.	3.2	31
44	Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0156910.	1.1	8
45	The Canary in the Coal Mine: The Growth of Patient-Derived Tumorgrafts in Mice Predicts Clinical Recurrence after Surgical Resection of Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1884-1892.	0.7	26
46	Expression of ERG protein in prostate cancer: variability and biological correlates. Endocrine-Related Cancer, 2015, 22, 277-287.	1.6	28
47	Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 1168-1175.	0.7	108
48	Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Laboratory Investigation, 2015, 95, 207-222.	1.7	45
49	Sclerosing Thymoma. Archives of Pathology and Laboratory Medicine, 2015, 139, 1068-1070.	1.2	5
50	SMAD4 Regulates Cell Motility through Transcription of N-Cadherin in Human Pancreatic Ductal Epithelium. PLoS ONE, 2014, 9, e107948.	1.1	31
51	Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery. Clinical Cancer Research, 2014, 20, 6529-6540.	3.2	75
52	Endoscopic modified Lothrop approach for the excision of bilateral frontal sinus tumors. Ear, Nose and Throat Journal, 2014, 93, 116-9.	0.4	0
53	The Expression of PTEN Is Associated With Improved Prognosis in Patients With Ampullary Adenocarcinoma After Pancreaticoduodenectomy. Archives of Pathology and Laboratory Medicine, 2013, 137, 1619-1626.	1.2	14
54	Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells. Clinical Cancer Research, 2013, 19, 549-559.	3.2	28

#	Article	IF	Citations
55	Pancreatic intraepithelial neoplasia and histological changes in nonâ€neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology, 2013, 63, 841-851.	1.6	34
56	Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1336-1343.	1.1	25
57	Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. American Journal of Surgical Pathology, 2012, 36, 409-417.	2.1	158
58	Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy. American Journal of Surgical Pathology, 2012, 36, 552-559.	2.1	53
59	In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. International Journal of Nanomedicine, 2012, 7, 1251.	3.3	96
60	Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma. Cancer, 2012, 118, 3182-3190.	2.0	216
61	Cytomegalovirus colitis presenting as massive lower gastrointestinal bleeding in an immunocompetent patient. Indian Journal of Surgery, 2008, 70, 28-31.	0.2	6